Lipocine (NASDAQ:LPCN) Rating Lowered to Hold at StockNews.com

StockNews.com downgraded shares of Lipocine (NASDAQ:LPCN) from a buy rating to a hold rating in a research note published on Saturday.

Separately, Alliance Global Partners assumed coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a buy rating and a $10.00 target price on the stock.

Lipocine Stock Down 3.6 %

NASDAQ LPCN opened at $4.33 on Friday. The stock’s 50-day simple moving average is $4.37 and its two-hundred day simple moving average is $5.57. Lipocine has a twelve month low of $2.31 and a twelve month high of $11.79. The company has a market capitalization of $23.16 million, a price-to-earnings ratio of -2.40 and a beta of 1.21.

Lipocine (NASDAQ:LPCN) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter. The firm had revenue of $0.09 million during the quarter. On average, equities analysts expect that Lipocine will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent quarter. 9.11% of the stock is owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.